Life Sciences

Holliston-based Harvard Apparatus Regenerative Technology Inc. (HART) reported a net quarterly loss $2.5 million, or 32 cents per share, higher than $2.1 million it lost in the same period in 2013.

Biotech firm Arrhythmia Research Technology of Fitchburg reported its second straight solid quarter, thanks to strong sales in its core product lines.

A follow-up study of patients with prostate cancer found improved survival rates for people using a drug from Generex, which has operations in Worcester.

Pharmaceutical giant Bristol-Myers Squibb, which has operations in Devens, has agreed to a joint venture with a Boston firm that will foster research and pre-clinical development of biopharmaceutical innovations from leading university research institutions across the United States, the companies announced.

Harvard Bioscience said a focus on its global growth strategy and a weaker dollar compared to the British pound and the Euro helped boost revenue slightly, as the life sciences manufacturer brought in $27 million.

Marlborough-based RXi Pharmaceuticals, a clinical-stage biotechnology company, has initiated a third phase 2 study of its anti-scarring drug RXI-109.

Revenues soared while profits sunk for Psychemedics Corp. of Acton in the second quarter of 2014.

Global sales for Illinois-based drug firm AbbVie rose 5 percent in the second quarter, driven primarily by a 26-percent jump in sales for its arthritis drug Humira.

rEVO Biologics of Framingham will begin the third testing phase of a drug intended to treat pre-eclampsia in pregnant women.

Strong sales from several divisions, as well as international growth of 7 percent, were tarnished by heavy expenses as Boston Scientific Corp. (BSX) reported a 97-percent drop in profits in its second-quarter financial results.